IL2 and neoplasm: The results revealed that local intracranial administration of IL-13Rα2-targeted CAR-T-cell therapy in combination with recombinant human IL-2 was well tolerated and resulted in transient tumor reduction or necrosis at the infusion site in four patients [63].